FindTrial
Sign In

Real-world study of Qinggan Formula combined with Lenvatinib and Sintilimab in the treatment of advanced unresectable liver cancer

Real-world study of Qinggan Formula combined with Lenvatinib and Sintilimab in the treatment of advanced unresectable liver cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000896
Enrollment
Unknown
Registered
2024-12-30
Start date
2024-09-27
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Qinggan Formula combined with Lenvatinib and Sintilimab treatment group:Qinggan Formula combined with Lenvatinib and Sintilimab treatment

Sponsors

Jining First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age: 18-75 years no gender restrictions. Diagnosed with advanced unresectable liver cancer with no other standard treatment options. ECOG performance status score of 0-1. Expected survival of =3 months. Signed informed consent and willingness to provide samples and attend follow-up as required.

Exclusion criteria

Exclusion criteria: Presence of other malignancies or severe heart or lung diseases. Active or uncontrolled infections. History of allergic reactions to the study drugs. Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
ORR;Lipid Metabolomics;Immunological markers;Gut Microbiome Metagenomics;—

Secondary

MeasureTime frame
PFS;OS;DCR;—

Countries

China

Contacts

Public ContactShulong Jiang

Jining First People's Hospital

jnsljiang@163.com15269720808

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026